Sign In to Follow Application
View All Documents & Correspondence

A Process Of Manufacturing A Composition And The Composition Obtained From The Afore Said Process For The Treatment Of Hair Loss

Abstract: This invention relates to a novel composition for the prophylaxis and treatment of hair loss. The formulation has the following ingredients and their proportion for each tablet. a) Lysine Hydrochloride 35% to 39% b) Ferrous Glycine sulphate 20% to 21% c) Calcium Pantothenate 3.5% to 4.9% d) Zinc Sulphate Monohydrate   2.66% to 2.68% e) Vitamin B12 0.0008% to 0.001% f) Biotin 0.6% to 0.7%

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
02 December 2009
Publication Number
23/2011
Publication Type
INA
Invention Field
PHARMACEUTICALS
Status
Email
Parent Application

Applicants

MMC HEALTHCARE LIMITED
34-B, SIDCO INDUSTRIAL ESTATE, THIRUMAZHISAI, CHENNAI - 602 107.

Inventors

1. M. RAJARATHINAM
34-B, SIDCO INDUSTRIAL ESTATE, THIRUMAZHISAI, CHENNAI - 602 107.

Specification

Field of Invention This invention relates to a composition and its manufacturing process of composition for the treatment of Hair loss. Prior Art Today one of the major problems of both men and women is Hair loss. The important reason for hair loss is nutritional deficiency. Nutrients are an integral part of maintaining healthy hair. A healthy diet may not provide the daily recommended allowance of nutrients. Hence the problem arises. Currently available treatments for hair loss are not taking care of route cause namely nutritional deficiency. Present methods of treatment as follows: 1. Local applications Though it results in hair growth in most patients, the hair grown is generally indeterminate rather than true terminal hair. The hair sheds when treatment is stopped. 2. Anti androgen therapy Anti-Androgen therapy with Systemic Androgen Receptor Protein inhibitors is suitable only for women. Since this class of systematic anti androgens decrease both testosterone and dihydrotestosterone (DHT) they have been seen to hold much promise to stimulate hair re-growth for women. These anti-androgens are contra indicated in men because of the possible adverse effects it can have such as impotence, decreased libido and feminization. 3. Hair transplantation therapy Hair transplantation is considered indispensable for hair restoration. But since It involves surgical procedure the human body does not always respond predictably. Although there are few disadvantages associated with hair transplants its advantages outweighs the disadvantages. While the existing methods are directed to only cure, our invention will address the prevention and cure. These therapies are not taking care the nutritional deficiency, our invention will do. Summary of invention: The present invention provides a medicament for the prophylaxis and treatment of hair loss, particularly telogen effluvium, in humans. It further provides a kit useful in a combination therapy for the treatment of hair loss. Scalp hair loss can be divided into the following three main groups and any one group or combinations of said groups may be operating in an individual at any point in time: 1. Hair loss caused by a reduction in the number of hairs per unit area (cm^); 2. Hair loss caused by a reduction in the diameter of hair; and 3. Hair loss caused by an increase in the number of hairs in the telogen (resting) phase, or an increase in the length of time (latency period) between the end of the telogen phase and the initiation of the next anagen (growing) phase. It is normal to lose some scalp hair each day. There are natural fluctuations in the hair cycle which in turn influence the amount of hair shed from the scalp on a daily basis. It is therefore important to establish if a problem involving excessive hair shedding really exists and that the individual has not just become aware of their normal daily loss. For most humans, scalp hair has a life cycle of between 1000 and 2000 days (23/4 and 51/2 years), following which there is a short period of rest (the telogen phase), which lasts approximately one hundred days. For the majority of its life cycle, scalp hair is in a growth phase known as the anagen phase. As the new hair grows up the follicle it loosens the old resting hair (telogen hair) which is usually dislodged with brushing, combing or shampooing. This cycle continues unless the hair metabolism is disturbed. Since shed hair is almost entirely telogen hair, the loss from the scalp is seen 10 to 12 weeks later. For normal individuals having 100,000 hairs, the above process results in about 100 hairs per day being lost from the scalp, while for individuals with 150,000 hairs around 150 per day are lost. These figures are for a 1000 day cycle. For a 2000 day cycle, these values would be halved. Scalp hair grows around 0.33 mm per day and with a growth cycle of 1000 days the hair would grow to a length of 33 cm and for 2000 days 66 cm. Most transient and temporary effects on the hair cycle, which also cause increased hair shedding, correct themselves and no further action is required. Sometimes it is difficult to determine if the natural rate of hair shedding has increased or excessive shedding has declined, since an individual may be unaware of their normal rate. However if a true problem exists, such as occurs in a nutritional imbalance, the consequences can be detected as a reduction in hair volume. This is because the prolonged effect upon the hair cycle causes significant change to the overall amount of hair present. The present invention provides the use of six ingredients in the manufacture of a medicament for the prophylaxis and treatment of hair loss. Hair losses due to nutritional factors are essentially of two types: • Skin scaling maladies resulting in hair loss • Follicular problems resulting in hair loss Nutritional Factors Initiating Scalp Scaling and Hair Loss Not all chronic scaling conditions of the scalp such as dandruff or seborrhoieic dermatitis that trigger hair shedding (telogen effluvium) and lead to noticeable thinning in hair density are related to nutritional deficiency. Yet many scientific findings associate scalp skin abrasions, chaffing and itching in the accompaniment of hair loss with nutritional imbalances. Thus, deficiency of nutrition such as biotin is known to set off dermatitis, which, in turn, initiates the process of continual hair loss. Nutritional Factors Damaging Hair Follicles And Causing Hair Loss Scalp hair loss without any associated scalp scaling is of follicular origin. What happens in such cases is that nutritional imbalances weaken the hair follicles and this prompts acute hair shedding (telogen effluvium) or chronic telogen effluvium. Chronic telogen effluvium or CTE may stem from a variety of causes -from iron deficiency to zinc deficiency to deficiency of essential amino acids, etc. This invention relates to a composition which is characterized by the following ingredients in the proportion as indicated: Each Caplet contains: Biotin - 2.25 to 2.75 mg Lysine - 299.75 to 300.25 mg Vitamin B12 - 7.25 to 7.75 meg Elemental Iron - 34.75 to 35.25 mg Zinc - 22.25 to 22.75 mg Calcium Pantothenate - 29.75 to 30.25 mg Our formulation is the appropriate combination to take care of nutritional deficiency. Thereby it prevents hair loss. Hence this is a unique design. Each ingredient namely Biotin, Lysine, Vitamin B12, Iron, Zinc and Calcium pantothenate plays an important role in the prevention of hair loss and composition of ingredients in the proportion mentioned herein produce the synergetic effect. The inventors made great effort to provide a composition which meet the requirement of the industry and overcome the problem associated in the prior art. Role of biotin in the composition is as follows: • It is the best l

Documents

Application Documents

# Name Date
1 2966-che-2009 form-3 02-12-2009.pdf 2009-12-02
2 2966-che-2009 form-2 02-12-2009.pdf 2009-12-02
3 2966-che-2009 form-18 02-12-2009.pdf 2009-12-02
4 2966-che-2009 form-1 02-12-2009.pdf 2009-12-02
5 2966-che-2009 description(complete) 02-12-2009.pdf 2009-12-02
6 2966-che-2009 claims 02-12-2009.pdf 2009-12-02
7 2966-che-2009 abstract 02-12-2009.pdf 2009-12-02
8 2966-che-2009 correspondence others 02-12-2009.pdf 2009-12-02
9 2966-CHENP-2009 POWER OF ATTORNEY 03-07-2013.pdf 2013-07-03
10 2966-CHENP-2009 CORRESPONDENCE OTHERS 03-07-2013.pdf 2013-07-03
11 2966-CHE-2009_EXAMREPORT.pdf 2016-07-02